Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Comparison: Immunogenic Peptide Characteristics

Sequence homology >98% human identity <90% human identity Non-self epitopes trigger T-cell recognition Native insulin (low) vs exenatide (high) Sequence matters more than modification type Aggregation state Monomeric in solution Oligomeric or fibrillary Aggreg

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Sequence homology
  • >98% human identity
  • <90% human identity
  • Non-self epitopes trigger T-cell recognition
  • Native insulin (low) vs exenatide (high)
  • Sequence matters more than modification type
  • Aggregation state
  • Monomeric in solution
  • Oligomeric or fibrillary
  • Aggregates crosslink B-cell receptors
  • Properly stored Thymalin vs heat-exposed samples
  • Storage failure = immunogenicity risk
  • Administration route
  • Intravenous
  • Subcutaneous/IM
  • Subcutaneous targets tissue APCs
  • IV immunoglobulin vs SC peptide analogs
  • Route determines APC exposure
  • Dosing pattern
  • Daily microdose or high-dose bolus
  • Weekly intermediate dose
  • Intermediate dosing avoids tolerance zones
  • Daily insulin vs weekly GLP-1
  • Frequency drives memory B-cell activation
  • Impurity profile
  • <0.01 EU/mg endotoxin
  • >0.1 EU/mg endotoxin
  • Endotoxin primes innate immunity
  • Mammalian-cell vs bacterial expression systems
  • Bacterial peptides carry adjuvant contamination